Please ensure Javascript is enabled for purposes of website accessibility

Why Guardant Health Stock Is Rising Today

By Keith Speights - Apr 1, 2021 at 11:05AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's newest product received a key approval in New York.

What happened

Shares of Guardant Health (GH -6.56%) were rising 4.7% higher as of 10:54 a.m. EDT on Thursday. The gain came after the company announced that its Guardant Reveal blood test received Clinical Laboratory Evaluation Program (CLEP) approval from the New York State Department of Health in detecting and monitoring residual disease in patients with early-stage cancer.

So what

The win in New York marked an important milestone for Guardant Health. The company launched its Guardant Reveal product earlier this year. CLEP approval will allow oncologists in the Empire State to use the liquid biopsy test in two ways: identifying high-risk patients with colorectal cancer who could benefit from adjuvant therapy and detecting cancer recurrence.

Guardant Health's opportunity for Guardant Reveal should be big. Colorectal cancer recurs in 10% to 30% of early-stage patients. There are currently over 1.5 million survivors of colorectal cancer in the country. Guardant Reveal can detect cancer recurrence months earlier than current tests and imaging by finding circulating tumor DNA in patients' blood. 

A DNA double helix against a purple background.

Image source: Getty Images.

Today's announcement isn't the only good news for the healthcare stock this week. On Tuesday, Guardant Health reported that the Centers for Medicare and Medicaid Services approved Advanced Diagnostic Laboratory Test (ADLT) status for the Guardant360 CDx test. This companion diagnostic product is the first liquid biopsy approved by the U.S. Food and Drug Administration for comprehensive tumor mutation profiling across all solid cancers. 

Now what

Look for Guardant Reveal to continue picking up momentum in the marketplace in the coming months. However, Guardant360 will remain the biggest growth driver for Guardant Health. The company also plans to launch a next-generation tissue assay later this year that could add another commercial winner to its product lineup. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Guardant Health, Inc. Stock Quote
Guardant Health, Inc.
$32.21 (-6.56%) $-2.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.